Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Report: Boom In 3D-Printed Medical Devices By 2022

Executive Summary

A new market report estimates the global health-care revenue from 3D-printed medical devices is likely to grow to almost $3 billion by 2022. FDA has a keen interest in understanding how to oversee production of 3D-printed devices that can be made anywhere, and device-makers are interested in the technology to develop products personalized to patients.

You may also be interested in...



3D Printing: Will Personalized Medical Devices Be The Next Big Thing?

Medical device manufacturers have a growing interest in 3D printing, a technology that could upend the manufacturing and distribution of certain medical devices and expand the scope of personalized medicine – especially in orthopedics, where it's used for some models, implants, and surgical cutting guides.

FDA Will Talk 3-D Printing At October Workshop

The Oct. 8-9 workshop will serve as a forum for FDA to collect public input on technical assessments that should be considered for 3-D printed devices to “provide a transparent evaluation process for future submissions.”

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel